BioSpace News Archive

Exosystems, an artificial intelligence -based digital healthcare company and a member of Born2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance Corporation.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half of 2021.

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its third quarter of 2021 ended September 30, 2021, after the market closes on Monday, November 8, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the third quarter 2021 before the market opens on Monday, November 15, 2021

Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), today announced that the Company will report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021 after U.S. markets close.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the following virtual investor conferences:

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the first quarter ended September 30, 2021, and an update on its pipeline of late-stage product candidates.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of its common stock at a public offering price of $25.00 per share.

Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the pricing of its underwritten initial public offering of 3,600,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $5.00.